2025
Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study.
Morales D, Bu F, Viernes B, DuVall S, Matheny M, Simon K, Falconer T, Richter L, Ostropolets A, Lau W, Man K, Chattopadhyay S, Mathioudakis N, Minty E, Nishimura A, Sun F, Yin C, Seager S, Chai Y, Zhou J, Lu Y, Reyes C, Pistillo A, Duarte-Salles T, Blacketer C, Schuemie M, Ryan P, Krumholz H, Hripcsak G, Khera R, Suchard M. Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study. Diabetes Care 2025 PMID: 40465422, DOI: 10.2337/dc25-0154.Peer-Reviewed Original ResearchRisk of thyroid tumorThyroid tumorsGLP-1RADPP-4isHazard ratioThyroid malignancyCohort studyIncreased riskSodium-glucose cotransporter 2 inhibitorsElectronic health record databaseGlucagon-like peptide 1 receptor agonistsEstimate hazard ratiosRandom-effects meta-analysisGLP-1 receptor agonistsPeptide 1 receptor agonistsDipeptidyl peptidase 4 inhibitorsThyroid tumor incidenceUsers of SGLT2isHealth record databaseSecond-line treatmentType 2 diabetes mellitusNew-user cohort studyRetrospective cohort studyUsers of sulfonylureasIntention-to-treatThe impact of food and drug administration-based eligibility criteria on demographic representation in current phase III clinical trials for newly diagnosed breast cancer.
Varma T, Merz L, Wang Y, Cronin A, Freedman R, Abel G, Hantel A. The impact of food and drug administration-based eligibility criteria on demographic representation in current phase III clinical trials for newly diagnosed breast cancer. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e23021.Peer-Reviewed Original ResearchFood and Drug Administration criteriaFood and Drug AdministrationFood and Drug Administration guidanceEligibility criteriaNH whitesNH BlackClinical trialsSafety dataNewly diagnosed breast cancerPhase III clinical trialsMedian differencePhase III trialsUS Food and Drug AdministrationCurative-intent therapyProportion of patientsIII clinical trialsNon-Hispanic (NH)Electronic health record databaseRestrictive eligibility criteriaIII trialsCreatinine clearancePrimary endpointMedian ageSecondary endpointsInvestigational agentsHuman Immunodeficiency Virus Infection and Long COVID: A RECOVER Program, Electronic Health Record–Based Cohort Study
Hawkins K, Dandachi D, Verzani Z, Brannock M, Lewis C, Abedian S, Jaferian S, Wuller S, Truong J, Witvliet M, Dymond G, Mehta H, Patel P, Hill E, Weiner M, Carton T, Kaushal R, Feuerriegel E, Tran H, Marks K, Oliveira C, Gardner E, Ofotokun I, Gulick R, Erlandson K. Human Immunodeficiency Virus Infection and Long COVID: A RECOVER Program, Electronic Health Record–Based Cohort Study. Clinical Infectious Diseases 2025, ciaf242. PMID: 40354184, DOI: 10.1093/cid/ciaf242.Peer-Reviewed Original ResearchDefinition of Long COVIDICD-10Baseline chronic conditionsLong COVIDElectronic health record databaseIncreased riskHealth record databaseICD-10 codesICD-10 definitionRisk of long COVIDClinical Research NetworkChronic conditionsAcute SARS-CoV-2 infectionHIV statusAnalytic sampleOdds ratioCohort definitionsCohort CollaborationComputable phenotypePhenotype definitionRecord databaseSARS-CoV-2 infectionLogistic regressionResearch NetworkMulticenter studyEffect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease
King A, Tan X, Dhopeshwarkar N, Bohn R, Dea K, Leonard C, de Havenon A. Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease. American Journal Of Preventive Cardiology 2025, 21: 100922. PMID: 39896054, PMCID: PMC11786665, DOI: 10.1016/j.ajpc.2024.100922.Peer-Reviewed Original ResearchVascular risk factorsGLP-1 RAsRisk factorsType 2 diabetesAtherosclerotic cardiovascular diseaseUS electronic health records databaseElectronic health record databaseOW GLP-1 RAsRisk factor valuesHealth record databaseCardiovascular diseaseReal-world practiceBody mass indexOnce-weeklyEffects of glucagon-like peptide-1 receptor agonistsGlucagon-like peptide-1 receptor agonistsGLP-1Systolic blood pressureLow-density lipoprotein cholesterolPeptide-1 receptor agonistsEffects of once-weeklyMass indexRecord databaseSignificant mean reductionAssociated with significant reductions
2024
Real-World Use Patterns and Clinical Outcomes for Myelodysplastic Syndrome Patients Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents
Zeidan A, Zhao R, Pierre-Victor D, Wang Y, Tepsick J, Lan Z, Salimi T. Real-World Use Patterns and Clinical Outcomes for Myelodysplastic Syndrome Patients Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents. Blood 2024, 144: 5189-5189. DOI: 10.1182/blood-2024-205495.Peer-Reviewed Original ResearchAML-free survivalTreated with hypomethylating agentsOral hypomethylating agentsHypomethylating agentsMyelodysplastic syndrome patientsMyelodysplastic syndromeDEC-CClinical characteristicsMDS diagnosisNext treatmentMonths median follow-upRisk of AML transformationHigh-risk myelodysplastic syndromeReal-world treatment outcomesTreatment of adult patientsHypomethylating agent treatmentKaplan-Meier survival analysis methodMedian Follow-UpCox regression analysisReal-world studyAML transformationHMA therapyOral decitabineECOG 0Electronic health record databaseSystemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors. JAMA Oncology 2024, 10: 887-895. PMID: 38753341, PMCID: PMC11099840, DOI: 10.1001/jamaoncol.2024.1129.Peer-Reviewed Original ResearchNational Quality ForumQuintile 5Quintile 1Improve end-of-life careEnd-of-life careCohort studyNationwide population-based cohort studyPopulation-based cohort studyEnd of lifeElectronic health record databaseHealth care practicesColorectal cancerPopulation of patientsCox proportional hazards modelsAmerican Society of Clinical OncologyQuality ForumCare practicesOverall survivalPayment incentivesProportional hazards modelHighest quintileMultivariate Cox proportional hazards modelQuintileFlatiron HealthHazard ratioCorrigendum to “AML-068 - Survival Differences in Patients With Acute Myeloid Leukemia (AML) Treated With Oral Azacitidine (Oral-AZA) as Maintenance and Those Eligible but Not Treated in a US Electronic Health Record (EHR) Database” [Clinical Lymphoma, Myeloma & Leukemia, 23S1 (2023) S1-S593]
Mims A, Xie Z, Vasconcelos A, Strocchia M, Heydendael W, Chevli M, Rotter D, Potluri R, Prebet T, Sieluk J. Corrigendum to “AML-068 - Survival Differences in Patients With Acute Myeloid Leukemia (AML) Treated With Oral Azacitidine (Oral-AZA) as Maintenance and Those Eligible but Not Treated in a US Electronic Health Record (EHR) Database” [Clinical Lymphoma, Myeloma & Leukemia, 23S1 (2023) S1-S593]. Clinical Lymphoma Myeloma & Leukemia 2024, 24: 203-204. DOI: 10.1016/j.clml.2023.11.010.Peer-Reviewed Original Research
2023
Chronic Cough: Characterizing and Quantifying Burden in Adults Using a Nationwide Electronic Health Records Database
Scierka L, Bradley B, Glynn E, Davis S, Hoffman M, Tam-Williams J, Mena-Hurtado C, Smolderen K. Chronic Cough: Characterizing and Quantifying Burden in Adults Using a Nationwide Electronic Health Records Database. Journal Of Healthcare Informatics Research 2023, 8: 50-64. PMID: 38273985, PMCID: PMC10805682, DOI: 10.1007/s41666-023-00150-5.Peer-Reviewed Original ResearchChronic coughChronic cough patientsAcute coughCough patientsElectronic health record databaseChronic pulmonary diseaseHealth care utilizationEHR-based dataHealth record databaseCough phenotypesCough episodesPulmonary diseaseCare utilizationDiseases codesCommon conditionCoughInternational ClassificationMore outpatientUnknown raceRecord databaseRisk profileOlder ageCohortEHR databaseQuantifying burdenThe Epidemiology of Palmoplantar Pustulosis: An Analysis of Multiple Health Insurance Claims and Electronic Health Records Databases
Ramcharran D, Strober B, Gordon K, DeKlotz C, Fakharzadeh S, Yang Y, Swerdel J, Hardin J, Dronavalli S, Paller A. The Epidemiology of Palmoplantar Pustulosis: An Analysis of Multiple Health Insurance Claims and Electronic Health Records Databases. Advances In Therapy 2023, 40: 5090-5101. PMID: 37737889, PMCID: PMC10567878, DOI: 10.1007/s12325-023-02669-w.Peer-Reviewed Original ResearchConceptsElectronic health record databaseHealth record databasePPP patientsRecord databaseHigher baseline useChronic inflammatory conditionsPost-diagnosis treatmentHealth insurance claimsConclusionsThe burdenPotential miscodingPalmoplantar pustulosisSterile pustulesBaseline characteristicsMetabolic syndromeBaseline useInflammatory conditionsIncidence ratePopulation-based approachPrevalence estimatesPPP prevalenceEpidemiologyAdditional studiesPustulosisDisease treatmentPatients
2022
Long-Term Opioid Therapy and Overdose in Patients With and Without Cancer (CO203A)
Merlin J, Black A, Troszak L, Giannitrapani K, Lorenz K. Long-Term Opioid Therapy and Overdose in Patients With and Without Cancer (CO203A). Journal Of Pain And Symptom Management 2022, 63: 1065-1066. DOI: 10.1016/j.jpainsymman.2022.04.013.Peer-Reviewed Original ResearchLong-term opioid therapyOpioid therapyOpioid prescriptionsOpioid overdoseElectronic health record databaseTerm opioid therapyCancer pain managementRetrospective cohort studyCox proportional hazardsOpioid overdose riskHealth record databaseYears of ageRole of cancerOpioid receiptCohort studyMost patientsPain managementOutpatient visitsInpatient admissionsVHA careOpioid risksDose/Inclusion criteriaOverdose riskLatent growth mixture modelingVariability in 30-day major amputation rates following endovascular peripheral vascular intervention for critical limb ischemia
Provance JB, Spertus JA, Jones PG, Hoffman MA, Bunte MC, Vogel TR, Mena-Hurtado C, Smolderen KG. Variability in 30-day major amputation rates following endovascular peripheral vascular intervention for critical limb ischemia. Vascular Medicine 2022, 27: 350-357. PMID: 35603755, DOI: 10.1177/1358863x221098097.Peer-Reviewed Original ResearchConceptsPeripheral vascular interventionsCritical limb ischemiaMedian risk ratioEndovascular peripheral vascular interventionsMajor amputation ratePatient-level factorsAmputation ratePVI procedureLimb ischemiaRisk ratioVascular interventionsNational electronic health record databaseElectronic health record databasePredictors of amputationRate of amputationMixed effects Poisson regression modelHealth record databaseEffects Poisson regression modelPoisson regression modelsCLI carePrevious amputationClinical factorsCLI treatmentBlack raceDiagnosis codesLong-term Opioid Therapy and Overdose in Patients with and without Cancer
Merlin J, Black A, Midboe A, Troszak L, Asch S, Bohnert A, Fenton B, Giannitrapani K, Glassman P, Kerns R, Silveira M, Lorenz K, Becker W. Long-term Opioid Therapy and Overdose in Patients with and without Cancer. Journal Of Pain 2022, 23: 60. DOI: 10.1016/j.jpain.2022.03.225.Peer-Reviewed Original ResearchLong-term opioid therapyOpioid therapyCox proportional hazard modelingElectronic health record databaseCancer pain managementRetrospective cohort studyProportional hazard modelingOpioid overdose riskHealth record databasePresence of cancerRole of cancerOpioid receiptCohort entryCohort studyHazard ratioMost patientsPain managementOpioid risksDose/Inclusion criteriaOpioid overdoseOverdose riskLatent growth mixture modelingLower riskPatientsAnalysis of Dual Combination Therapies Used in Treatment of Hypertension in a Multinational Cohort
Lu Y, Van Zandt M, Liu Y, Li J, Wang X, Chen Y, Chen Z, Cho J, Dorajoo SR, Feng M, Hsu MH, Hsu JC, Iqbal U, Jonnagaddala J, Li YC, Liaw ST, Lim HS, Ngiam KY, Nguyen PA, Park RW, Pratt N, Reich C, Rhee SY, Sathappan SMK, Shin SJ, Tan HX, You SC, Zhang X, Krumholz HM, Suchard MA, Xu H. Analysis of Dual Combination Therapies Used in Treatment of Hypertension in a Multinational Cohort. JAMA Network Open 2022, 5: e223877. PMID: 35323951, PMCID: PMC8948532, DOI: 10.1001/jamanetworkopen.2022.3877.Peer-Reviewed Original ResearchConceptsDual combination therapyUse of ACEIAntihypertensive drug classesProportion of patientsKhoo Teck Puat HospitalCombination therapyUniversity Hospital databaseHospital databaseDrug classesDual combinationSouth Western Sydney Local Health DistrictWestern Sydney Local Health DistrictPatients age 65 yearsSydney Local Health DistrictElectronic health record databasePatients age 18Local Health DistrictAge 65 yearsTreatment of hypertensionHealth record databaseARB monotherapyTreatment escalationAdult patientsCohort studyCombination regimenExtracting Patient-level Social Determinants of Health into the OMOP Common Data Model.
Phuong J, Zampino E, Dobbins N, Espinoza J, Meeker D, Spratt H, Madlock-Brown C, Weiskopf N, Wilcox A. Extracting Patient-level Social Determinants of Health into the OMOP Common Data Model. AMIA Annual Symposium Proceedings 2022, 2021: 989-998. PMID: 35308947, PMCID: PMC8861735.Peer-Reviewed Original Research
2021
Comprehensive Characterization of COVID-19 Patients with Repeatedly Positive SARS-CoV-2 Tests Using a Large U.S. Electronic Health Record Database
Dong X, Zhou Y, Shu X, Bernstam E, Stern R, Aronoff D, Xu H, Lipworth L. Comprehensive Characterization of COVID-19 Patients with Repeatedly Positive SARS-CoV-2 Tests Using a Large U.S. Electronic Health Record Database. Microbiology Spectrum 2021, 9: 10.1128/spectrum.00327-21. PMID: 34406805, PMCID: PMC8552669, DOI: 10.1128/spectrum.00327-21.Peer-Reviewed Original ResearchConceptsPositive SARS-CoV-2 testSARS-CoV-2 testSecond positive testElectronic health record databaseCases of reinfectionHealth record databasePositive testPositive SARS-CoV-2 PCR test resultsSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testingSARS-CoV-2 PCR test resultsRecord databaseSevere acute respiratory syndrome coronavirus 2Intensive care unit admissionAcute respiratory syndrome coronavirus 2SARS-CoV-2 infectionRespiratory syndrome coronavirus 2Long-term health consequencesLarge electronic health record databasePotential long-term health consequencesCare unit admissionOverweight/obeseChronic medical conditionsPositive molecular testCOVID-19 patientsSyndrome coronavirus 2
2019
Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis
Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, Reich CG, Duke J, Madigan D, Hripcsak G, Ryan PB. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. The Lancet 2019, 394: 1816-1826. PMID: 31668726, PMCID: PMC6924620, DOI: 10.1016/s0140-6736(19)32317-7.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCalcium Channel BlockersChildCohort StudiesComparative Effectiveness ResearchDatabases, FactualDiureticsEvidence-Based MedicineFemaleHeart FailureHumansHypertensionMaleMiddle AgedMyocardial InfarctionStrokeYoung AdultConceptsNon-dihydropyridine calcium channel blockersCalcium channel blockersThiazide-like diureticsChannel blockersEnzyme inhibitorsDrug classesHazard ratioCurrent guidelinesFirst-line antihypertensive drug classesComparative effectivenessFirst-line drug classesNew-user cohort designDihydropyridine calcium channel blockerElectronic health record databaseFirst-line classesAngiotensin receptor blockersAntihypertensive drug classesAcute myocardial infarctionHealth record databaseReal-world evidenceMedical Research CouncilMillions of patientsAustralian National HealthOptimal monotherapyReceptor blockers
2017
Racial disparities in the use of programmed death-1 checkpoint inhibitors.
O'Connor J, Seidl-Rathkopf K, Torres A, You P, Nussbaum N, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy A, Gross C. Racial disparities in the use of programmed death-1 checkpoint inhibitors. Journal Of Clinical Oncology 2017, 35: 3068-3068. DOI: 10.1200/jco.2017.35.15_suppl.3068.Peer-Reviewed Original ResearchDeath-1 checkpoint inhibitorsElectronic health record databaseLines of therapySystemic therapyCheckpoint inhibitorsCancer clinicRacial disparitiesAdvanced non-small cell lung cancerNon-small cell lung cancerMetastatic renal cell carcinomaAnti-PD1 treatmentCell lung cancerRenal cell carcinomaHealth record databaseSignificant racial disparitiesNew cancer drugsSquamous histologyStudy drugReal-world practiceAdvanced melanomaTherapy linesWhite patientsMale sexCell carcinomaLung cancerAdoption of immunotherapy into real-world practice: Insights from the use of checkpoint inhibitors.
O'Connor J, Seidl-Rathkopf K, You P, Nussbaum N, Torres A, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy A, Gross C. Adoption of immunotherapy into real-world practice: Insights from the use of checkpoint inhibitors. Journal Of Clinical Oncology 2017, 35: e14583-e14583. DOI: 10.1200/jco.2017.35.15_suppl.e14583.Peer-Reviewed Original ResearchElectronic health record databaseReal-world practiceCheckpoint inhibitorsAdvanced non-small cell lung cancerFDA approvalNon-small cell lung cancerDeath-1 checkpoint inhibitorsMetastatic renal cell carcinomaAdoption of immunotherapyGeneralizability of trialsCell lung cancerRenal cell carcinomaDrug Administration approvalHealth record databaseChi-square testStudy drugOlder patientsSystemic therapyAdvanced melanomaMedian ageTherapy linesCell carcinomaLung cancerAdministration approvalClinical trials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply